<DOC>
	<DOC>NCT02600364</DOC>
	<brief_summary>The purpose of this study is to assess safety and effectiveness of the p64 Flow Modulation Device.</brief_summary>
	<brief_title>Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device</brief_title>
	<detailed_description>Title: Diversion-p64. Device: p64 Flow Modulation Device. Study design: Prospective, multicenter, single arm Post Market Clinical Follow-Up Study. Purpose: To assess safety and effectiveness of p64. Study duration: 30 months. Sample Size: 107 patients. Number of sites: up to 20. Follow-up intervals: 3-6 and 12 months clinical and angiographic follow-up.</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<criteria>1. Age â‰¥ 18 2. Patient harbours either a saccular or dissecting or blisterlike or fusiform intracerebral aneurysm or an intracerebral segmental disease, in the anterior circulation for which the indication for p64 treatment is given 3. Patient or legal representative provides written informed consent verifying that he/she consents to the use of his/her data (according to the data protection laws) 1. Aneurysms of the posterior circulation 2. Imaging evidence of bifurcation aneurysms 3. Imaging evidence of dissections 4. Imaging evidence of fistulae 5. Imaging evidence of arteriovenous malformations 6. Patient is harbouring another aneurysm that has to be treated within six months after first procedure 7. Known allergy to study medication, e.g. ASA, Clopidogrel, Heparin or contrast media 8. Pregnant or breast feeding women or women with childbearing potential who cannot provide a negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Aneurysm</keyword>
	<keyword>intracerebral</keyword>
	<keyword>stroke</keyword>
	<keyword>p64</keyword>
</DOC>